Activation of Src signaling mediates acquired resistance to ALK inhibition in lung cancerRyohei Yoshida, Yoshinobu Ohsaki|International Journal of Oncology|2017Cited by 34
The feasibility of circulating tumor DNA analysis as a marker of recurrence in triple-negative breast cancerYoshinobu Ohsaki|Oncology Letters|2021Cited by 7
SETD2 and miR-21 as therapeutic targets for NUT midline carcinomaNana Yoshida, Yoshinobu Ohsaki|Research Square|2021Cited by 0